Abstract Number: 286 • 2018 ACR/ARHP Annual Meeting
The Prevalence and Treatment Patterns of Women of Childbearing Age with Rheumatic Diseases
Background/Purpose: Emerging data on exposure of infants to therapeutics through placental transfer and breastmilk could impact the management of women of childbearing age (WoCBA) with…Abstract Number: 81 • 2017 ACR/ARHP Annual Meeting
Selective Inhibition of the Immunoproteasome Subunit LMP7 Is Not Sufficient for Blocking Cytokine Production or Attenuating Progression of Experimental Arthritis
Background/Purpose: The proteasome inhibitor (PI) PR-957/ONX 0914 blocks cytokine production in vitro and attenuates disease progression in experimental models of rheumatoid arthritis (RA) (Nature Medicine…Abstract Number: 509 • 2017 ACR/ARHP Annual Meeting
Long-Term Safety and Efficacy of Upadacitinib (ABT-494), an Oral JAK-1 Inhibitor in Patients with Rheumatoid Arthritis in an Open Label Extension Study
Background/Purpose: Upadacitinib (UPA, ABT-494) is a selective, oral JAK-1 inhibitor studied in two phase 2 randomized controlled trials (RCTs) in patients (pts) with rheumatoid arthritis…Abstract Number: 536 • 2017 ACR/ARHP Annual Meeting
Effectiveness, Tolerability, and Safety of Tofacitinib in Rheumatoid Arthritis: A Retrospective Analysis of Real-World Data from the St. Gallen Cohort
Background/Purpose: Tofacitinib is an oral JAK inhibitor for the treatment of RA. Efficacy and safety of tofacitinib have been shown in several clinical studies. The…Abstract Number: 1299 • 2017 ACR/ARHP Annual Meeting
Patient-Reported Disease Activity and Adverse Pregnancy Outcomes in Systemic Lupus Erythematosus and Rheumatoid Arthritis
Background/Purpose: Patient-reported measures of disease activity may provide useful adjuncts to physician-reported measures in identifying pregnancies at greater risk for adverse pregnancy outcomes. Little is…Abstract Number: 118 • 2017 Pediatric Rheumatology Symposium
Oxygen Saturation Recordings in Pediatric Rheumatology Patients At Risk For Lung Disease
Background/Purpose: Pediatric rheumatology patients are at high risk for the development of pulmonary disease. Lung disease in these patients can go unnoticed for long periods…Abstract Number: 438 • 2016 ACR/ARHP Annual Meeting
Glucocorticoid Adverse Effects – the Patient Perspective
Background/Purpose: Glucocorticoid (GC) use and adverse effects (AEs) are prevalent in rheumatic diseases, yet there is no standardized patient-reported outcome measure to assess benefit and…Abstract Number: 932 • 2016 ACR/ARHP Annual Meeting
High Symptom Prevalence and Under-Utilisation of Palliative Care at End-of-Life of Patients with Systemic Rheumatic Diseases
Background/Purpose: Patients with rheumatic diseases may have systemic complications from disease as well as therapy and often suffer symptoms towards the end-of-life comparable to patients…Abstract Number: 1352 • 2016 ACR/ARHP Annual Meeting
Predictors of Mortality in Rheumatic Disease Patients with CMV Infection
Background/Purpose: Immunosuppressive therapy, which is frequently used to treat various rheumatic diseases, increases risk of opportunistic infection. However, few reports were available on the prognosis…Abstract Number: 2458 • 2016 ACR/ARHP Annual Meeting
Erectile Dysfunction in Men with Rheumatic Diseases: A Systematic Review
Background/Purpose: Given the obvious female predominance of rheumatic diseases, significant attention has already been drawn to the impact of these conditions on female sexual function.…Abstract Number: 3023 • 2016 ACR/ARHP Annual Meeting
Lipid Profile and Effect of Statin Treatment in Pooled Phase 2 and Phase 3 Baricitinib Studies
Background/Purpose: In patients with active RA an increase in lipid analytes has been observed after treatment with janus kinase inhibitors and other disease-modifying antirheumatic drugs.1…Abstract Number: 1215 • 2015 ACR/ARHP Annual Meeting
Air Pollution and the Rheumatic Diseases: A Systematic Review and Meta-Analysis
Background/Purpose: Environmental risk factors, such as air pollution, have been studied in relation to the risk of development of rheumatic diseases, including rheumatoid arthritis (RA),…Abstract Number: 1352 • 2015 ACR/ARHP Annual Meeting
How Frequently Does Tuberculosis Screening Test Become Positive in Rheumatic Patients Treated with ANTI-Tumor Necrosis Factor-ALPHA Therapy? an Analysis of Risk Factors
Background/Purpose: Anti-tumor necrosis factor-α (TNF-α) therapy is associated with an increased risk of mycobacterium tuberculosis infection. Tuberculosis (TB) reactivation can lead to severe complications in…Abstract Number: 1888 • 2015 ACR/ARHP Annual Meeting
There Is a Need for New Systemic Sclerosis Subset Criteria: A Content Analytic Approach
Background/Purpose: Systemic sclerosis (SSc) is a family of diseases unified by the presence of immune activation, vasculopathy and fibrosis. The concept of SSc subsets cannot…Abstract Number: 2525 • 2015 ACR/ARHP Annual Meeting
Patterns and Secular Trends in Use of Immunosuppressive Agents during Pregnancy in Women with Rheumatologic Conditions
Background/Purpose: Systemic inflammatory conditions such as systemic lupus erythematosus (SLE), rheumatoid arthritis (RA), psoriatic arthritis (PsA), and ankylosing spondylitis (AS) affect many women during their…